The burden of chronic insomnia on patients

Module 1
Module 2
Module 3
Module 4
Module 5
Module 6
Back to home

Click here for prescribing information and adverse event reporting information (hosted externally).

Module 1
Module 2
Module 3
Module 4
Module 5
Module 6

The burden of chronic insomnia on patients

Definition of chronic insomnia1

  • Difficulty falling or staying asleep, early awakening or non‑restorative sleep, which results in impaired daytime functioning or wellbeing
  • With daytime symptoms that may include fatigue, low mood or irritability, malaise, and cognitive impairment
  • Symptoms experienced several times a week for at least 3 months

Insomnia is predicted to affect approximately one third of adults at some point in their lives.2 Additionally, recovery from chronic insomnia is low, with a 38% persistence rate over a 5‑year period.3

Of these, the prevalence of chronic insomnia is more likely in:

females

(68% vs 32%
of males)5

older adults

(30% more likely compared with younger adults)6

Prevalence is unaffected by socioeconomic and employment status.5

Despite its widespread prevalence, chronic insomnia is a woefully under‑reported health condition, through a lack of:7

  • help‑seeking on the part of the patient
  • recognition or screening in primary care

Ready for the next step?

Risk factors for insomnia

Continue to next topic
Continue to next topic

QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.34

This information is intended for UK healthcare professionals.

▼This medicine is subject to additional monitoring.

Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to ds.safety.uk@idorsia.com

References

  1. World Health Organization (WHO). International statistical classification of diseases and related health problems (ICD) 11th revision. Available at: icd.who.int. Accessed August 2025
  2. Hafner M, Romanelli R J et al. The societal and economic burden of insomnia in adults: an international study. RAND Corporation, 2023
  3. Morin C M, Jarrin D C et al. Incidence, persistence, and remission rates of insomnia over 5 years. JAMA Netw Open 2020;3(11):e2018782
  4. Johnson E O, Roth T et al. Epidemiology of DSM-IV insomnia in adolescence: lifetime prevalence, chronicity, and an emergent gender difference. Pediatrics 2006;117(2):e247-256
  5. Bhaskar S, Hemavathy D, Prasad S. Prevalence of chronic insomnia in adult patients and its correlation with medical comorbidities. J Family Med Prim Care 2016;5(4):780‑784
  6. Klink M E, Quan S F et al. Risk factors associated with complaints of insomnia in a general adult population. Influence of previous complaints of insomnia. Arch Intern Med 1992;152(8):1634‑1637
  7. Torrens Darder I, Argüelles‑Vázquez R et al. Primary care is the frontline for help‑seeking insomnia patients. Eur J Gen Pract 2021;27(1):286‑293
  8. St‑Onge M P, Mikic A, Pietrolungo C E. Effects of diet on sleep quality. Adv Nutr 2016;7(5):938‑949
  9. Dolezal B A, Neufeld E V et al. Interrelationship between sleep and exercise: a systematic review. Adv Prev Med 2017;2017:1364387
  10. Burns A C, Saxena R et al. Time spent in outdoor light is associated with mood, sleep, and circadian rhythm-related outcomes: a cross-sectional and longitudinal study in over 400,000 UK Biobank participants. J Affect Disord 2021;295:347-352
  11. Nowakowski S, Meers J, Heimbach E. Sleep and women’s health. Sleep Med Res 2013;4(1):1‑22
  12. Neubauer D N. Sleep problems in the elderly. Am Fam Physician 1999;59(9):2551‑2558, 2559‑2560
  13. Park S Y, Oh M K et al. The effects of alcohol on quality of sleep. Korean J Fam Med 2015;36(6):294‑299
  14. Riemann D, Baglioni C et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017;26(6):675‑700
  15. Morin C M, Drake C L et al. Insomnia disorder. Nat Rev Dis Primers 2015;1:15026
  16. Li J, Vitiello M V, Gooneratne N S. Sleep in normal aging. Sleep Med Clin 2018;13(1):1‑11
  17. Ferri P, Guadi M et al. The impact of shift work on the psychological and physical health of nurses in a general hospital: a comparison between rotating night shifts and day shifts. Risk Manag Healthc Policy 2016;9:203‑211
  18. Oh C M, Kim H Y et al. The effect of anxiety and depression on sleep quality of individuals with high risk for insomnia: a population‑based study. Front Neurol 2019;10:849
  19. Ezzie M E, Parsons J P, Mastronarde J G. Sleep and obstructive lung diseases. Sleep Med Clin 2008;3(4):505‑515
  20. Lim D C, Najafi A et al. The need to promote sleep health in public health agendas across the globe. Lancet Public Health 2023;8(10):e820‑e826
  21. Singh N, Wanjari A, Sinha A. Effects of nicotine on the central nervous system and sleep quality in relation to other stimulants: a narrative review. Cureus 2023;15(11):e49162
  22. Drake C, Roehrs T et al. Caffeine effects on sleep taken 0, 3, or 6 hours before going to bed. J Clin Sleep Med 2013;9(11):1195‑1200
  23. National Institute for Health and Care Excellence (NICE). Clinical knowledge summary. Insomnia. Scenario: managing short-term insomnia (less than 3 months duration), May 2025. Available at: cks.nice.org.uk. Accessed August 2025
  24. Kang J, Chen S. Effects of an irregular bedtime schedule on sleep quality, daytime sleepiness, and fatigue among university students in Taiwan. BMC Public Health 2009;9:248
  25. Blume C, Garbazza C, Spitschan M. Effects of light on human circadian rhythms, sleep and mood. Somnologie (Berl) 2019;23(3):147‑156
  26. National Institute for Health and Care Excellence (NICE). Clinical knowledge summary. Insomnia, May 2025. Available at: cks.nice.org.uk. Accessed August 2025
  27. Babson K A, Trainor C D et al. A test of the effects of acute sleep deprivation on general and specific self‑reported anxiety and depressive symptoms: an experimental extension. J Behav Ther Exp Psychiatry 2010;41(3):297‑303
  28. Minkel J D, Banks S et al. Sleep deprivation and stressors: evidence for elevated negative affect in response to mild stressors when sleep deprived. Emotion 2012;12(5):1015‑1020
  29. Dinges D F, Pack F et al. Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4‑5 hours per night. Sleep 1997;20(4):267‑277
  30. Astill R G, Van der Heijden K B et al. Sleep, cognition, and behavioral problems in school‑age children: a century of research meta‑analyzed. Psychol Bull 2012;138(6):1109‑1138
  31. Chen T Y, Lee S, Buxton O M. A greater extent of insomnia symptoms and physician‑recommended sleep medication use predict fall risk in community‑dwelling older adults. Sleep 2017;40(11): doi:10.1093/sleep/zsx142
  32. Centers for Disease Control and Prevention (CDC). Facts about falls, May 2023. Available at: cdc.gov. Accessed August 2025
  33. Léger D, Bayon V et al. Insomnia and accidents: cross-sectional study (EQUINOX) on sleep-related home, work and car accidents in 5293 subjects with insomnia from 10 countries. J Sleep Res 2014;23(2):143‑152
  34. QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics

© NICE 2023 Daridorexant for treating long-term insomnia. Available from www.nice.org.uk/guidance/ta922. All rights reserved. Subject to Notice of rights.

NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/ publication.

UK-DA-00658 | Date of preparation: September 2025

Copyright © 2026 Idorsia Pharmaceuticals Ltd
Our Services
PI & AE